| 초록 |
Translating nanoparticle-based agents into clinical applications still remains a challenge due to the difficulty in regulating interactions occurring at the interfaces between nanoparticles and biological systems. Upon contact with physiological environments, a nanoparticle interacts biomolecules, induces a protein layer on its surface, and complicates its biological effects, resulting in the loss of the targeting specificity and rapid clearance via phagocyte system. In this talk, we present a new targeting strategy for nanoparticles incorporated with a pre-coated protein corona shield. The protein corona shield featuring recombinant fusion proteins generically combined HER2-binding affibody molecules prevented non-specific interactions with serum proteins while ensuring systematic targeting functions in vitro and in vivo. This study provides a new insight into the use of the protein corona as a targeting agent with specificity. |
